title: Single and multiple dose pharmacokinetics of rifapentine in man: part II.
abstract: OBJECTIVE
  To characterize the pharmacokinetics of rifapentine following single, multiple, and intermittent doses.
  
  
  METHODS
  Twenty-three healthy male volunteers were randomized in a two-period, incomplete block, crossover design to receive two of four possible treatments: single daily oral rifapentine doses of 150, 300, or 600 mg given on day 1 and again on days 4-10, or a single oral 600 mg dose given on days 1, 4, 7, and 10.
  
  
  RESULTS
  Maximum rifapentine plasma concentrations were observed in 4-5 hours. Mean rifapentine t(1/2) ranged from 13.2-14.1 hours and was similar across the 150-600 mg dose range. The changes in rifapentine Cmax (R = 0.86) and AUC(0-->infinity) (R + 0.90) were dose linear. The active 25-desacetyl metabolite appeared slowly in plasma, with mean Tmax of 14.4-17.8 hours. Mean t(1/2) for 25-desacetyl-rifapentine ranged from 13.3-24.3 hours. Disproportionate, dose-dependent increases in rifapentine and 25-desacetyl-rifapentine AUC were observed as single doses of rifapentine increased from 150 to 600 mg. At steady state, however, the magnitude of dose dependency was much less.
  
  
  CONCLUSIONS
  Maximum plasma rifapentine concentrations were well above minimum inhibitory concentrations for Mycobacterium tuberculosis and M. avium following single 600 mg doses. In addition, the extended t(1/2) of rifapentine and its active metabolite support clinical investigation of once or twice-weekly rifapentine dosage regimens of rifapentine for the management of tuberculosis.
authors.affiliation: Drug Metabolism/Pharmacokinetics Department, Schering Plough Research Institute, Kenilworth, New Jersey 07033-0539, USA. anther.keung@spcorp.com
authors.forename: A
authors.initials: A
authors.lastname: Keung
authors.forename: M G
authors.initials: MG
authors.lastname: Eller
authors.forename: K A
authors.initials: KA
authors.lastname: McKenzie
authors.forename: S J
authors.initials: SJ
authors.lastname: Weir
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D006801:Humans; D008297:Male; D012293:Rifampin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics
chemical_list: D000995:Antitubercular Agents; D012293:Rifampin; C018421:rifapentine